Cjc-1295 Shop

Sourcing High-Purity CJC-1295 for Laboratory Research

A specialized CJC-1295 shop provides institutional laboratories with analytical-grade tetrasubstituted growth hormone-releasing hormone (GHRH) analogs designed strictly for scientific evaluation. Sourcing research-grade CJC-1295 requires verified purity via HPLC and Mass Spectrometry, comprehensive lot-specific Certificates of Analysis, low endotoxin levels, and full chemical traceability to ensure reproducible in vitro and preclinical experimental outcomes.

When establishing preclinical study models involving the somatotropic axis, research institutions require reference-standard materials that perform predictably across varied assay parameters. Substandard peptides containing chemical impurities, truncation sequences, or residual TFA salts can alter cellular responses and obscure experimental data. PX1 Research operates as a dedicated laboratory vendor, supplying fully characterized research peptides manufactured under strict quality systems.

Every batch offered through our operational catalog undergoes rigorous identity, purity, and stability testing. Researchers can investigate targeted GHRH receptor binding dynamics, downstream cellular signaling, and tissue repair pathways with full confidence in reagent integrity.

Chemical Structure and GHRH Receptor Mechanism of Action

CJC-1295 is a synthetic 29-amino-acid peptide derivative of endogenous growth hormone-releasing hormone (GHRH 1-29). The molecule incorporates four strategic amino acid substitutions at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). These structural modifications enhance enzymological resistance against rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and cleavage by serum endopeptidases, significantly extending its functional half-life compared to native GHRH.

At the cellular level, CJC-1295 acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a G-protein-coupled receptor primarily expressed on anterior pituitary somatotropes. Upon receptor binding, CJC-1295 stimulates the Gs alpha subunit, activating adenylate cyclase. This intracellular signaling cascade increases cyclic adenosine monophosphate (cAMP) accumulation and activates protein kinase A (PKA), ultimately triggering the transcription and pulsatile secretion of endogenous growth hormone (GH).

Preclinical studies suggest that sustained GHRH-R activation by CJC-1295 promotes steady, physiological stimulation of somatotropes. This mechanism permits the continuous activation of the downstream somatotropic axis, encouraging downstream synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1) in hepatocyte and peripheral tissue culture models.

Preclinical Applications and the GH/IGF-1 Somatotropic Axis

In experimental biology, CJC-1295 is widely utilized to investigate the mechanisms governing somatotropic regulation, cellular repair, and metabolic modulation. Because native GHRH exhibits an extremely brief plasma half-life (approximately 7 to 12 minutes in rodent and canine models), long-acting analogs like CJC-1295 allow investigators to observe sustained somatotroph stimulation without requiring continuous intravenous infusion systems.

Preclinical literature demonstrates that extended elevation of systemic GH and downstream IGF-1 levels profoundly impacts tissue regeneration models. In vitro assays using skeletal muscle progenitor cells and tenocytes indicate that GHRH receptor signaling enhances collagen deposition, promotes myoblast proliferation, and accelerates cellular migration during wound repair simulations. To further explore these cellular dynamics, consult our detailed analysis on GHRH analogs guide.

Furthermore, animal models evaluating metabolic regulation show that sustained CJC-1295 administration influences lipid turnover, nitrogen retention, and glucose homeostasis. Researchers investigating hepatic IGF-1 transcription frequently utilize CJC-1295 to delineate receptor desensitization thresholds and feedback loop kinetics within the hypothalamic-pituitary-somatotropic axis.

Structural Variations: CJC-1295 With DAC vs. CJC-1295 Without DAC

When reviewing options within a CJC-1295 shop, researchers must distinguish between two primary chemical variants: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (frequently referred to as Modified GRF 1-29). While both peptides share identical tetrasubstituted amino acid backbone sequences, the presence of the DAC moiety fundamentally alters pharmacokinetic profiles.

CJC-1295 with DAC incorporates a maleimido-propionic acid linker bound to the lysine residue at C-terminus position 30. In biological fluids, this reactive group forms a stable, covalent bond with circulating serum albumin. This bioconjugation shields the peptide from renal clearance and enzymatic breakdown, extending the functional half-life in rodent models to several days. Investigators interested in long-duration somatotroph stimulation can examine our fully characterized CJC-1295 with DAC product.

Conversely, CJC-1295 without DAC (Modified GRF 1-29) lacks this albumin-binding conjugate. It exhibits a shorter, highly predictable half-life of approximately 30 minutes in preclinical models, making it ideal for experiments requiring rapid, acute GH release without persistent baseline elevations. For transient, pulse-like GHRH signaling studies, researchers utilize our certified CJC-1295 No DAC product.

Comparative Analysis: GHRH Analogs and GHRP Secretagogues

Understanding how CJC-1295 compares to other secretagogues is vital when designing comparative receptor binding assays or combination secretagogue protocols. While CJC-1295 operates exclusively through the GHRH receptor pathway, ghrelin receptor agonists (GHRPs) stimulate growth hormone release via an entirely independent mechanism.

To establish topical context across secretagogue classes, consider the distinct operational parameters of these key research compounds:

1. **CJC-1295**: Selective GHRH receptor agonist that enhances cAMP-dependent GH synthesis and secretion. Provides synergistic GH amplification when co-administered in vitro with ghrelin mimetics. 2. **Ipamorelin**: A highly selective growth hormone secretagogue receptor (GHSR-1a) agonist. Unlike earlier GHRPs, Ipamorelin demonstrates negligible stimulation of cortisol or prolactin, making it a clean control for GHSR-1a-specific signaling pathways. 3. **Sermorelin**: The non-tetrasubstituted, synthetic sequence corresponding to endogenous GHRH (1-29) amide. Sermorelin retains native receptor affinity but exhibits a significantly shorter enzymatic half-life due to vulnerability to DPP-IV cleavage.

In preclinical model comparisons, combining a GHRH agonist like CJC-1295 with a GHSR agonist like Ipamorelin results in a synergistic, rather than additive, surge in pulsatile GH release. This synergistic effect occurs because the two pathways activate distinct intracellular secondary messengers (cAMP/PKA and IP3/DAG/calcium mobilization, respectively). Learn more about these dual-pathway dynamics in our overview of growth hormone secretagogues.

Reconstitution, Handling, and Storage Protocols for Laboratory Use

Maintaining peptide stability is essential for preserving structural integrity and achieving reproducible experimental results. CJC-1295 is supplied as a lyophilized (freeze-dried) sterile cake contained within sealed glass vials. To prevent thermal degradation during transit, all orders ship directly from primary facilities located in California and Arizona.

Upon receipt, un-reconstituted lyophilized vials should be stored in a commercial laboratory freezer at -20°C or -80°C for long-term stability. Lyophilized peptides are susceptible to moisture absorption; vials should be allowed to acclimate to room temperature before opening to minimize condensation risk.

Reconstitution must be performed under aseptic conditions using bacteriostatic water containing 0.9% benzyl alcohol or sterile deionized water, depending on the requirements of the downstream assay. Reconstitution fluids should be introduced slowly down the internal glass wall of the vial, followed by gentle swirl motion. High-shear mechanical agitation or vigorous shaking must be avoided, as shear stress can cause peptide denaturing or aggregation.

Once reconstituted, aqueous solution aliquots should be maintained at 2°C to 8°C and evaluated within short temporal windows to limit hydrolysis. For extended testing periods across multiple assay cycles, reconstituted stock solutions should be divided into single-use sub-aliquots and frozen at -80°C, avoiding repeated freeze-thaw cycles. Detailed reconstitution guidelines and concentration calculators are published within the PX1 Research hub.

Supplier Quality Metrics: Analytical Verification and Lot Traceability

Evaluating a CJC-1295 shop requires assessing the vendor's analytical rigor and manufacturing standard operating procedures. Lower-tier suppliers frequently rely on non-verified self-analysis or batch-blended documentation, introducing unacceptable risk into scientific investigations.

PX1 Research enforces strict quality control across every production lot. Prior to release, each batch undergoes dual analytical testing:

• **Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC)**: Assesses exact chemical purity, ensuring freedom from synthesis failure sequences, truncated peptides, and deamidation artifacts. PX1 guarantees a minimum target purity of 99% for research peptides. • **Electrospray Ionization Mass Spectrometry (ESI-MS)**: Verifies the exact molecular weight and chemical identity of the peptide sequence, confirming correct amino acid composition.

Furthermore, every shipment includes accessible, lot-specific Certificates of Analysis (COAs) generated by independent ISO 17025 accredited testing laboratories. Complete chain-of-custody and lot traceability ensure that investigators receive identical, reference-standard material across longitudinal study timelines.

Endotoxin Testing and Sterility Assurance in Peptide Synthesis

In cell culture assays, primary tissue cultures, and animal models, bacterial endotoxin contamination poses a critical threat to data integrity. Endotoxins—lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria—trigger severe inflammatory cascades, altered cytokine expression, and cell toxicity independent of the peptide's true mechanism.

PX1 Research subjects all CJC-1295 lots to quantitative Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels fall strictly below rigorous threshold limits (typically < 0.01 EU/μg). Synthesis occurs in state-of-the-art GMP-compliant facilities utilizing automated solid-phase peptide synthesis (SPPS) platforms.

Following synthesis and cleavage, peptides undergo ultrafiltration, lyophilization in ISO Class 5 cleanroom environments, and sealing under inert atmospheric gas to eliminate environmental contaminants. These measures guarantee that primary cell cultures and tissue preparations respond solely to the intended GHRH agonist activity.

Procurement and Institutional Account Operations at PX1 Research

PX1 Research acts as a trusted supply partner for university research centers, biotechnology firms, and contract research organizations (CROs). We maintain consistent inventory levels across all major catalog items, enabling prompt order processing and reliable same-day dispatch for orders received Monday through Friday.

To accommodate scale-up requirements, institutional purchasers can establish dedicated supply pipelines. Large-scale animal studies or high-throughput screening campaigns benefit from bulk batch reserving, custom vial sizing, and specialized packaging. Contact our institutional team to review account structures and volume options at wholesale peptide supply.

By prioritizing rigorous analytical validation, USA-based dispatch, and transparent documentation, PX1 Research provides the reliable foundation necessary for high-impact preclinical research.